| Not Yet Recruiting | A Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQH3906 Capsules in the Treatment of Active P Psoriatic Arthritis | Phase 2 | 2026-04-01 |
| Not Yet Recruiting | Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors Advanced Solid Tumor | Phase 1 / Phase 2 | 2026-04-01 |
| Not Yet Recruiting | A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorect HER2 IHC3+ Advanced Colorectal Cancer | Phase 3 | 2026-03-01 |
| Recruiting | A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Pl Multiple Myeloma | Phase 1 | 2025-12-09 |
| Recruiting | A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Recepto HER2-positive Breast Cancer | Phase 3 | 2025-09-15 |
| Recruiting | A Clinical Trial Evaluating TQB2101 in Subjects With Advanced Hematologic Malignancies Advanced Hematologic Malignancies | Phase 1 | 2025-08-01 |
| Completed | Clinical Trial of TQC2938 Injection in Patients With Seasonal Allergic Rhinitis Seasonal Allergic Rhinitis | Phase 2 | 2025-07-31 |
| Recruiting | TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-typ RAS/BRAF Wild Type Colorectal Cancer | Phase 1 / Phase 2 | 2025-07-30 |
| Recruiting | TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer HER2-positive Advanced Breast Cancer | Phase 3 | 2025-07-25 |
| Recruiting | A Clinical Trial Evaluating Injection of TQB6411 in Subjects With Advanced Malignant Tumors Advanced Malignant Tumors | Phase 1 | 2025-07-15 |
| Recruiting | Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced B Metastatic Breast Cancer | Phase 3 | 2025-07-07 |
| Recruiting | A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Breast Cancer | Phase 3 | 2025-06-23 |
| Completed | Clinical Trial to Evaluate the Tolerance of TQB2210 Injection Advanced Malignant Tumours | Phase 1 | 2025-05-16 |
| Recruiting | A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined W Pancreatic Cancer | Phase 2 | 2025-04-18 |
| Recruiting | Clinical Studies for the Treatment of Advanced Solid Tumors Advanced Solid Tumor | Phase 1 / Phase 2 | 2025-04-08 |
| Not Yet Recruiting | To Evaluate the Tolerability and Pharmacokinetics of TQB2101 for Injection in Patients With Advanced Malignant Breast Cancer, Lung Cancer, Colorectal Cancer | Phase 1 | 2025-04-01 |
| Active Not Recruiting | A Clinical Study to Evaluate the Efficacy and Safety of TQC2938 in Patients With Moderate to Severe Chronic Ob Chronic Obstructive Pulmonary Disease | Phase 2 | 2025-03-17 |
| Recruiting | A Clinical Trial of TQB2102 for Injection in Gynecological Tumors With Recurrent/Metastatic Advanced Gynecological Tumors | Phase 2 | 2025-03-13 |
| Not Yet Recruiting | Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulce Inflammatory Bowel Diseases | Phase 1 | 2025-01-01 |
| Recruiting | A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma Multiple Myeloma | Phase 1 | 2024-11-28 |
| Recruiting | A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Gastroesophageal Adenocarcinoma | Phase 2 | 2024-11-21 |
| Recruiting | The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast C Breast Cancer | Phase 2 | 2024-11-14 |
| Not Yet Recruiting | A Clinical Trial to Evaluate the Safety and Tolerability of TQB3911 Tablets in Patients With BCR::ABL Fusion G Chronic Myelogenous Leukemia | Phase 1 | 2024-11-01 |
| Not Yet Recruiting | Clinical Trial of TQB2928 in Combination With a Third-Generation Epidermal Growth Factor Receptor (EGFR) Tyros Advanced Non-small Cell Lung Cancer | Phase 1 | 2024-09-01 |
| Completed | Treatment of Moderate to Severe Plaque Psoriasis Plaque Psoriasis | Phase 2 | 2024-08-27 |
| Recruiting | A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality Non-Small Cell Lung Cancer | Phase 2 | 2024-08-06 |
| Recruiting | A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer Biliary Tract Cancer | Phase 1 / Phase 2 | 2024-07-22 |
| Completed | A Extension Clinical Study of TQC2731 Injection in the Treatment of Chronic Sinusitis With Nasal Polyps Chronic Rhinosinusitis With Nasal Polyps | Phase 2 | 2024-07-04 |
| Active Not Recruiting | A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP) Generalized Pustular Psoriasis | Phase 1 | 2024-06-19 |
| Unknown | A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia Hemophilia A | Phase 3 | 2024-04-01 |
| Recruiting | Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatme Pancreatic Neoplasms | Phase 2 | 2024-03-19 |
| Terminated | TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Soli Osteosarcoma, Other Solid Tumors | Phase 1 | 2024-02-15 |
| Completed | A Clinical Trial of TQH3906 Capsules in Healthy Volunteers Psoriasis | Phase 1 | 2024-02-02 |
| Recruiting | Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers Advanced Cancer | Phase 1 | 2024-02-01 |
| Completed | A Clinical Study of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps. Sinusitis | Phase 2 | 2023-12-28 |
| Completed | A Clinical Study of TQH2929 in Healthy Adult Subjects Psoriasis | Phase 1 | 2023-11-21 |
| Recruiting | A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer Breast Cancer | Phase 1 | 2023-11-17 |
| Terminated | TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) Mantle Cell Lymphoma | Phase 1 / Phase 2 | 2023-10-05 |
| Recruiting | Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjec Non-alcoholic Steatohepatitis | Phase 2 | 2023-09-14 |
| Unknown | Clinical Trial Evaluating the Safety of the TQB2103 for Injection Advanced Malignant Neoplasm | Phase 1 | 2023-07-04 |
| Unknown | A Clinical Trial of TQC2938 Injection in Healthy Adult Subjects Asthma | Phase 1 | 2023-06-13 |
| Unknown | A Clinical Trial of AP026 (TQA2226) for Injection in Adult Subjects. Diabetes Mellitus, Type 2 | Phase 1 | 2023-05-24 |
| Active Not Recruiting | Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers Advanced Cancer | Phase 1 | 2023-03-09 |
| Unknown | A Study of TQH2722 Injection to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Immunogenici Atopic Dermatitis | Phase 1 | 2022-06-01 |
| Terminated | Clinical Trial of TQB2858 Injection in the Treatment of Advanced High-grade Sarcoma Advanced High-grade Sarcoma | Phase 2 | 2022-05-09 |
| Unknown | Clinical Trial of the TQB2930 Injection in Patients With Advanced Cancers Advanced Cancers | Phase 1 | 2022-05-01 |
| Unknown | Clinical Trial of TQB2868 Injection in Subjects With Advanced Malignant Tumors Advanced Malignant Tumor | Phase 1 | 2022-04-27 |
| Terminated | A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreat Pancreatic Carcinoma | Phase 1 | 2022-03-24 |
| Unknown | Clinical Trial of TQB2825 in Subjects With CD20 Positive Hematological Tumors Hematological Tumors | Phase 1 | 2022-03-22 |
| Unknown | Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB2916 Injection in Patients With Advance Advanced Tumors | Phase 1 | 2022-02-01 |
| Unknown | Clinical Trial of the TQB2928 Injection in Patients With Advanced Cancers Advanced Cancer | Phase 1 | 2022-01-24 |